Cat. No.: HY-14596

Genistein

(Synonyms: NPI 031L)

88 Cited Publications

고객리뷰

Based on 88 publication(s) in Google Scholar

Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.82%
CAS No.: 446-72-0
화학식: C₁₅H₁₀O₅
분자량:270.24

보관:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Genistein Chemical Structure

CAS No.: 446-72-0

사이즈

가격

재고

수량

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

견적 받기 Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability 견적 받기 Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

대량구매 문의

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (88)
용액&용해도
- In Vitro
- In Vivo
Protocol
순도&문서
References
Help & FAQs
Bioz

Biological Activity

제품 설명

IC₅₀ & Target^[1]

EGFR

0.6 μM (IC₅₀, Cell Assay)

All EGFR Isoforms :

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	EC₅₀	108 μM Compound: 2	Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
A-431	EC₅₀	278 μM Compound: 2	Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
A549	IC₅₀	43.09 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 21129977]
A549	IC₅₀	64 μM Compound: Gen	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
AGS	IC₅₀	41.67 μM Compound: 1	Cytotoxicity against human AGS cells after 72 hrs by MTT assay Cytotoxicity against human AGS cells after 72 hrs by MTT assay	[PMID: 21129977]
ANN-1	IC₅₀	8 μM Compound: (1a) genistein	Cytotoxic effect on v-abl transformed murine ANN-1 cells Cytotoxic effect on v-abl transformed murine ANN-1 cells	[PMID: 8201603]
B16-F10	IC₅₀	79.21 μM Compound: 3	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 27720556]
BALB/3T3	IC₅₀	183.9 μM Compound: 9	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
Balb/MK	IC₅₀	9.1 μM Compound: Genistein	Tested for antiproliferative activity using mouse epidermal keratinocytes cell line (BALB/MK) Tested for antiproliferative activity using mouse epidermal keratinocytes cell line (BALB/MK)	[PMID: 7608909]
BJ	EC₅₀	>86.2069 μM Compound: 2	Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
BT-20	IC₅₀	46 μM Compound: Genistein	Antiproliferative activity against human BT20 cell line by MTT assay Antiproliferative activity against human BT20 cell line by MTT assay	[PMID: 16789737]
BV-2	IC₅₀	28.4 μM Compound: 6	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production	[PMID: 29482940]
BXPC-3	IC₅₀	30 μM Compound: Genistein	Antiproliferative activity against human BxPC3 cell line by MTT assay Antiproliferative activity against human BxPC3 cell line by MTT assay	[PMID: 16789737]
BXPC-3	IC₅₀	79 μM Compound: Gen	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
C8166	CC₅₀	36.2 μg/mL Compound: 7	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	13.9 μg/mL Compound: 7	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
Caco-2	IC₅₀	>100 μM Compound: 1	Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 21129977]
COLO 201	IC₅₀	73 μM Compound: Gen	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
COLO357	IC₅₀	50 μM Compound: Genistein	Antiproliferative activity against human COLO357 cell line by MTT assay Antiproliferative activity against human COLO357 cell line by MTT assay	[PMID: 16789737]
DLD-1	IC₅₀	50 μM Compound: 51	Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability by MTS assay Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability by MTS assay	[PMID: 33445154]
DU-145	ED₅₀	2.39 μg/mL Compound: 5	Cytotoxicity against human DU145 cells after 6 days by MTT assay Cytotoxicity against human DU145 cells after 6 days by MTT assay	[PMID: 12088420]
DU-145	IC₅₀	47.29 μM Compound: 1	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 21129977]
DU-145	IC₅₀	>100 μM Compound: Genistein	Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
HCT-116	IC₅₀	34.9 μM Compound: 1	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 21129977]
HEK293	IC₅₀	22 μM Compound: genistein	Antagonist activity at human recombinant LXRbeta expressed in HEK293 cells by luciferase reporter gene assay Antagonist activity at human recombinant LXRbeta expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 18343126]
HEK293	IC₅₀	31 μM Compound: genistein	Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 18343126]
HEK293	IC₅₀	16.5 μM Compound: 21	Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol	[PMID: 18533708]
HEK293	IC₅₀	2.21 μM Compound: 21	Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol	[PMID: 18533708]
HEK293	IC₅₀	>100 μM Compound: Genistein	Inhibition of Src (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay Inhibition of Src (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay	[PMID: 25205190]
HEK293	IC₅₀	25.12 μM Compound: Genistein	Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay	[PMID: 25205190]
HEK293	IC₅₀	58.18 μM Compound: Genistein	Inhibition of Fyn (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay Inhibition of Fyn (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay	[PMID: 25205190]
HEK293	IC₅₀	67.99 μM Compound: Genistein	Inhibition of Bmx (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay Inhibition of Bmx (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay	[PMID: 25205190]
HeLa	EC₅₀	4.1 nM Compound: genistein	Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta. Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta.	[PMID: 11906280]
HeLa	EC₅₀	48 nM Compound: genistein	Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha. Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha.	[PMID: 11906280]
HeLa	EC₅₀	73 nM Compound: genistein	Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay	[PMID: 16610787]
HeLa	EC₅₀	956 nM Compound: genistein	Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay at 10 uM Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay at 10 uM	[PMID: 16610787]
HepG2	IC₅₀	>100 μM Compound: Genistein	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26896708]
HepG2	EC₅₀	67.6945 μM Compound: 2	Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Hs-578T	ED₅₀	3.5 μg/mL Compound: 5	Cytotoxicity against human Hs 578T cells after 6 days by MTT assay Cytotoxicity against human Hs 578T cells after 6 days by MTT assay	[PMID: 12088420]
Hs746T	ED₅₀	5.82 μg/mL Compound: 5	Cytotoxicity against human Hs 746T cells after 6 days by MTT assay Cytotoxicity against human Hs 746T cells after 6 days by MTT assay	[PMID: 12088420]
HT-29	IC₅₀	52.78 μM Compound: 1	Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 21129977]
HT-29	IC₅₀	50 μM Compound: Gen	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Huh-7	CC₅₀	>50 μM Compound: 23	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	14.4 μM Compound: 23	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Huh-7	IC₅₀	20 μM Compound: Genistein	Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei ANKA expressing GFP infected in human HuH7 cells assessed as inhibition of parasite development after 24 hrs by qRT-PCR analysis Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei ANKA expressing GFP infected in human HuH7 cells assessed as inhibition of parasite development after 24 hrs by qRT-PCR analysis	[PMID: 24125849]
HUVEC	IC₅₀	88 μM Compound: 13	Cytotoxicity against HUVEC after 24 hrs by MTT assay Cytotoxicity against HUVEC after 24 hrs by MTT assay	[PMID: 17591441]
Ishikawa	IC₅₀	0.51 μM Compound: genistein	Estrogenic activity in human Ishikawa cells assessed as induction of alkaline phosphatase activity after 4 days by para-nitrophenol release assay Estrogenic activity in human Ishikawa cells assessed as induction of alkaline phosphatase activity after 4 days by para-nitrophenol release assay	[PMID: 12502307]
K562	IC₅₀	17.56 μM Compound: 1	Growth inhibition of K562 cells by XTT assay after 5 days Growth inhibition of K562 cells by XTT assay after 5 days	[PMID: 17411092]
KB	ED₅₀	6.7 μg/mL Compound: NSC-36586	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]
KOPN-8	EC₅₀	>86.2069 μM Compound: 2	Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
L02	IC₅₀	>100 μM Compound: Genistein	Cytotoxicity against human LO2 cells after 48 hrs by MTT assay Cytotoxicity against human LO2 cells after 48 hrs by MTT assay	[PMID: 26896708]
LN-229	IC₅₀	44 μM Compound: Gen	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LNCaP	IC₅₀	30.65 μM Compound: 1	Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay	[PMID: 21129977]
LNCaP	IC₅₀	37.4 μM Compound: Genistein	Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
LNCaP	IC₅₀	10 μM Compound: Genistein	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 29456113]
LNCaP	IC₅₀	24 μM Compound: Genistein	Antiproliferative activity against human LNCAP cells after 72 hrs by MTS assay Antiproliferative activity against human LNCAP cells after 72 hrs by MTS assay	[PMID: 29456113]
LNCaP	IC₅₀	31.7 μM Compound: Genistein	Antiproliferative activity against human LNCAP cells after 72 hrs in presence of enzalutamide by MTS assay Antiproliferative activity against human LNCAP cells after 72 hrs in presence of enzalutamide by MTS assay	[PMID: 29456113]
LNCaP	IC₅₀	65 μM Compound: Genistein	Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human LNCap cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 60 mins by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human LNCap cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 60 mins by fluorescence based method	[PMID: 30776692]
LNCaP-Clone-FGC	ED₅₀	25.45 μg/mL Compound: 5	Cytotoxicity against human LNCaP-FGC cells after 6 days by MTT assay Cytotoxicity against human LNCaP-FGC cells after 6 days by MTT assay	[PMID: 12088420]
LoVo	IC₅₀	15.88 μM Compound: 1	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21129977]
MCF7	IC₅₀	>30 μM Compound: genistein	Cytotoxicity against human MCF7 cells after 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs	[PMID: 10075742]
MCF7	IC₅₀	26 μM Compound: genistein	Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs	[PMID: 10075742]
MCF7	GI₅₀	10 μM Compound: 2	Antiproliferative activity against estrogen receptor expressing human MCF7 cells Antiproliferative activity against estrogen receptor expressing human MCF7 cells	[PMID: 19818612]
MCF7	IC₅₀	1 μM Compound: genistein	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20813524]
MCF7	IC₅₀	1 x 10^-6 M Compound: genistein	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20813524]
MCF7	IC₅₀	62.71 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 21129977]
MCF7	IC₅₀	8.8 μM Compound: 28	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	[PMID: 21354800]
MCF7	IC₅₀	50 nM Compound: Genistein	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	15.1 μM Compound: (1a) genistein	Cytotoxic effect on MCF-7 human breast carcinoma cells Cytotoxic effect on MCF-7 human breast carcinoma cells	[PMID: 8201603]
MCF7	IC₅₀	11 μM Compound: genistein	Anti-proliferative activity against estrogen-responsive human breast cancer cell line MCF-7 in the presence of ER at a 10e-4 uM concentration of estradiol Anti-proliferative activity against estrogen-responsive human breast cancer cell line MCF-7 in the presence of ER at a 10e-4 uM concentration of estradiol	[PMID: 8784443]
MCF7	IC₅₀	77 μM Compound: genistein	Inhibition of 10e-4 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation Inhibition of 10e-4 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation	[PMID: 8784443]
MDA-MB-231	IC₅₀	43 μM Compound: Gen	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDA-MB-436	GI₅₀	17 μM Compound: 2	Antiproliferative activity against estrogen receptor expressing human MDA-MB-436 cells Antiproliferative activity against estrogen receptor expressing human MDA-MB-436 cells	[PMID: 19818612]
MDCK	IC₅₀	6.9 μM Compound: 28	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	[PMID: 21354800]
Melan-a	IC₅₀	57.83 μM Compound: 6	Inhibition of melanin formation in mouse Melan-a cells after 5 days by ELISA Inhibition of melanin formation in mouse Melan-a cells after 5 days by ELISA	[PMID: 20022495]
NCI-H460	IC₅₀	47 μM Compound: Gen	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Neutrophil	IC₅₀	0.54 μg/mL Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins	[PMID: 21353775]
Neutrophil	IC₅₀	6.99 μg/mL Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins	[PMID: 21353775]
Neutrophil	IC₅₀	0.69 μM Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced superoxide anion production treated 5 mins before FMLP addition measured after 10 mins Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced superoxide anion production treated 5 mins before FMLP addition measured after 10 mins	[PMID: 23822585]
Neutrophil	IC₅₀	6.72 μM Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced elastase release treated 5 mins before FMLP addition Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced elastase release treated 5 mins before FMLP addition	[PMID: 23822585]
Neutrophil	IC₅₀	1.11 μM Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLF/cytochalasin B-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins by spectrophotometric analysis Antiinflammatory activity in human neutrophils assessed as inhibition of fMLF/cytochalasin B-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins by spectrophotometric analysis	[PMID: 32359855]
NIH3T3	EC₅₀	4.4 μM Compound: Genistein	Agonist activity at CFTR-deltaF508 mutant expressed in NIH3T3 cells assessed as increase in forskolin-stimulated current Agonist activity at CFTR-deltaF508 mutant expressed in NIH3T3 cells assessed as increase in forskolin-stimulated current	[PMID: 18595696]
NIH3T3	IC₅₀	24 μM Compound: (1a) genistein	Cytotoxic effect on 3T3 cells Cytotoxic effect on 3T3 cells	[PMID: 8201603]
PANC-1	IC₅₀	87 μM Compound: Gen	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PC-3	IC₅₀	50 μM Compound: Genistein	Antiproliferative activity against human PC3 cell line by MTT assay Antiproliferative activity against human PC3 cell line by MTT assay	[PMID: 16789737]
PC-3	IC₅₀	65.17 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21129977]
PC-3	IC₅₀	68.6 μM Compound: Genistein	Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
Peritoneal macrophage	IC₅₀	16.87 μM Compound: 120	Antiinflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as TNF-alpha level Antiinflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as TNF-alpha level	[PMID: 37683361]
RAW	IC₅₀	18.1 μM Compound: genistein	Inhibition of 1 ug/ml LPS-stimulated TNFalpha accumulation in RAW 264 cells after 24 hrs Inhibition of 1 ug/ml LPS-stimulated TNFalpha accumulation in RAW 264 cells after 24 hrs	[PMID: 17320246]
RAW264.7	IC₅₀	26.5 μM Compound: Genistein	Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay	[PMID: 19278854]
RAW264.7	IC₅₀	26 μM Compound: Genistein	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent	[PMID: 20363145]
RAW264.7	IC₅₀	19.1 μM Compound: Genistein	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production treated 2 hrs before LPS challenge measured after 24 hrs by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production treated 2 hrs before LPS challenge measured after 24 hrs by ELISA	[PMID: 21288727]
RAW264.7	IC₅₀	>50 μM Compound: 10	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25592708]
RAW264.7	IC₅₀	11.4 μM Compound: Genistein	Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-induced osteoclast differentiation after 4 to 5 days by TRAP assay Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-induced osteoclast differentiation after 4 to 5 days by TRAP assay	[PMID: 28169537]
RAW264.7	IC₅₀	>1 μM Compound: 19	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay	[PMID: 29932657]
SEM	EC₅₀	59.338 μM Compound: 2	Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Sf9	IC₅₀	>100 μM Compound: 10	Inhibition of His6-tagged human recombinant DNMT3A/DNMT3L expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid Inhibition of His6-tagged human recombinant DNMT3A/DNMT3L expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid	[PMID: 25406944]
Sf9	IC₅₀	30 μM Compound: 10	Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintil	[PMID: 25406944]
SH-SY5Y	EC₅₀	1.7 nM Compound: genistein	Agonist activity in transcriptional activation assay in SH-SY5Y neuroblastoma cells expressing Estrogen receptor beta Agonist activity in transcriptional activation assay in SH-SY5Y neuroblastoma cells expressing Estrogen receptor beta	[PMID: 11906280]
SK-BR-3	IC₅₀	96.7 μM Compound: 1	Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay	[PMID: 21129977]
SK-BR-3	EC₅₀	403 μM Compound: 2	Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
SK-BR-3	EC₅₀	97 μM Compound: 2	Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
SK-MEL-2	IC₅₀	36 μM Compound: Gen	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
SUP-B15	EC₅₀	>86.2069 μM Compound: 2	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
T47D	IC₅₀	48 μM Compound: Gen	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T98G	IC₅₀	89.41 μM Compound: 1	Cytotoxicity against human T98G cells after 72 hrs by SRB assay Cytotoxicity against human T98G cells after 72 hrs by SRB assay	[PMID: 21129977]
U-87MG ATCC	IC₅₀	55 μM Compound: Gen	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-937	IC₅₀	>100 μM Compound: 5	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	48 μM Compound: 5	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	72 μM Compound: 5	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]
UoC-B1	EC₅₀	35.6958 μM Compound: 2	Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Ventricular myocyte	IC₅₀	11 μM Compound: Genistein	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]
Ventricular myocyte	IC₅₀	20 μM Compound: Genistein	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	[PMID: 22761000]
Vero	IC₅₀	32.9 μM Compound: Genistein	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 16441066]
Vero	CC₅₀	>50 μM Compound: 64	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 33539089]
WiDr	IC₅₀	27.7 μM Compound: (1a) genistein	Cytotoxic effect on WiDr human colon cells Cytotoxic effect on WiDr human colon cells	[PMID: 8201603]

In Vitro

Genistein inhibits serum-stimulated growth of MCF-7 and T47D ER⁺ cells with IC₅₀ values of 7.6 and 8.7 μg/mL by dye exclusion, respectively, and 8.7 and 10.6 μg/mL by [³H]thymidmne incorporation, respectively. These values are similar to the IC₅₀ values of 9.4 and 7 μg/mL for MCF-7 and T47D ER⁺ cells, respectively, obtained with the MTT assay. Additionally, Genistein at concentrations up to 20 μg/mL does not alter MTT mitochondrial reduction when compared to control cells in an 8 h incubation period. Furthermore, neither biochanin A or daidzein are found to interfere with the MTT assay at IC₅₀ concentrations. Therefore, the MTT assay is valid for determining growth inhibition by Genistein at concentrations under 20 μg/mL in the systems studied^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bisphenol A (BPA) treatment alone and combined with Genistein had no significant effect on the protein expression of LC3II and PPARα in liver of STD- or HFD-fed rats (P>0.05; P>0.05). Significant decreasing of the protein expression of PPARγ in liver is observed when Genistein is added to rats, compared to either HFD group or HFD-BPA group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 446-72-0
Appearance Solid
분자량 270.24
화학식 C₁₅H₁₀O₅
Color White to yellow
SMILES

OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
Synonyms

NPI 031L
Structure Classification
- Flavonoids
- Isoflavones
- Phenols
- Polyphenols
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (88)

All Flow Cytometry

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Condensate nanovaccine adjuvants augment CD8+ T-Cell-dependent antitumor immunity through mtDNA leakage-triggered cGAS-STING axis activation. [Abstract]

2025 Oct 21;10(1):349. PMID: 41115902

Genistein purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 21;10(1):349. [Abstract]

Analysis of the cellular uptake pathways of OVA PCD. Ethamilamiline (EIPA), genistein (GEN, 200 μM), and chlorpromazine (CPZ), pretreated for 4 h, subsequently incubated with FITC-labeled OVA PCD for 12 h were used to inhibit macropinocytosis, caveolin-mediated endocytosis, and clathrin-mediated endocytosis, respectively (n = 5).
Cell

Microbiome metabolism of dietary phytochemicals controls the anticancer activity of PI3K inhibitors. [Abstract]

2025 May 29;188(11):3065-3080.e21. PMID: 40393457
Nat Nanotechnol

A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. [Abstract]

2020 Dec;15(12):1043-1052. PMID: 33139933

Genistein purchased from MedChemExpress. Usage Cited in: Nat Nanotechnol. 2020 Dec;15(12):1043-1052. [Abstract]

Flow cytometry measured the FITC MFI of CD11c+ BMDCs for BMDCs incubated with F7-PEI/FITC-OVA or F13-PEI/FITC-OVA, w/wo adding indicated endocytosis inhibitors (n = 3). BMDCs were incubated with genistein (700μM) for 30min before the addition of F7-PEI/OVA-FITC or F13-PEI/OVA-FITCNPs.
Nat Immunol

Microbiota-shaped neutrophil senescence regulates sexual dimorphism in bladder cancer. [Abstract]

2025 Apr 11. PMID: 40217111

Genistein purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Apr 11. [Abstract]

Flow cytometry analysis of FDG MFI of neutrophils treated with dimethyl sulfoxide (DMSO) or different metabolites; the neutrophil FDG MFI ratio of metabolites relative to DMSO was calculated (n = 3).
Nat Biomed Eng

In situ formation of biomolecular condensates as intracellular drug reservoirs for augmenting chemotherapy. [Abstract]

2024 Nov;8(11):1469-1482. PMID: 39271933

Genistein purchased from MedChemExpress. Usage Cited in: Nat Biomed Eng. 2024 Nov;8(11):1469-1482. [Abstract]

Cellular uptake pathway of different formulations. Cells were pretreated 2h with methyl-β-cyclodextrin (MCD), genistein (Gen, 200 µM), amiloride (AMI) or chlorpromazine (CPZ), to block lipid raft, caveolae-mediated endocytosis, micropinocytosis and clathrin-mediated endocytosis, respectively.
Bioact Mater

Antibody-activated trans-endothelial delivery of mesoporous organosilica nanomedicine augments tumor extravasation and anti-cancer immunotherapy. [Abstract]

2021 Jan 14;6(7):2158-2172. PMID: 33511314

Genistein purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Jan 14;6(7):2158-2172. [Abstract]

Transcytosis efficiency of FITC-labelled aPD/IND@MON-IgG and aPD/IND@MON-aANN at 30 min and 60 min in the transcytosis model pretreated with or without 200 μM genistein (endocytic pathway inhibitor) or 20 μM EXO1 (exocytic pathway inhibitor) for 2h.
Adv Funct Mater

2024 Oct 31.
Cell Host Microbe

Immunometabolic reprogramming of macrophages by gut microbiota-derived cadaverine controls colon inflammation. [Abstract]

2025 Sep 30:S1931-3128(25)00375-0. PMID: 41033313
ACS Nano

Enzyme-Triggered Transcytosis of Dendrimer-Drug Conjugate for Deep Penetration into Pancreatic Tumors. [Abstract]

2020 Apr 28;14(4):4890-4904. PMID: 32286784
Adv Sci (Weinh)

Screening and Identification of Novel DNA Aptamer for Targeted Delivery to Injured Podocytes in Glomerular Diseases. [Abstract]

2025 Apr 3:e2412356. PMID: 40178289
Adv Sci (Weinh)

Plac1+ Tumor Cell-Treg Interplay Supports Tumorigenesis and Progression of Head and Neck Cancer. [Abstract]

2025 May;12(17):e2417312. PMID: 40056047
Adv Sci (Weinh)

CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy. [Abstract]

2023 Jun;10(17):e2207017. PMID: 37092579
Nat Plants

An apoplastic fungal effector disrupts N-glycosylation of ZmLecRK1, inducing its degradation to suppress disease resistance in maize. [Abstract]

2025 Sep 12. PMID: 40940425
Theranostics

Oxidative stress-mediated PANoptosis and ferroptosis: Exploration of multimodal cell death triggered by an AIE-active nano-photosensitizer via photodynamic therapy. [Abstract]

2025 Jun 9;15(14):6665-6685. PMID: 40585993
Theranostics

Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis. [Abstract]

2021 May 24;11(15):7308-7321. PMID: 34158852
Theranostics

A Multifunctional Nanotherapy for Targeted Treatment of Colon Cancer by Simultaneously Regulating Tumor Microenvironment. [Abstract]

2019 May 31;9(13):3732-3753. PMID: 31281510
Chem Eng J

2025 Jul 1.
Biomaterials

Biodegradable polymers with tertiary amines enhance mRNA delivery of lipid nanoparticles via improved endosomal escape. [Abstract]

2026 Jan:324:123541. PMID: 40644791
Microbiome

The gut microbiome in patients with Cushing's disease affects depression- and anxiety-like behavior in mice. [Abstract]

2024 Nov 1;12(1):225. PMID: 39482760
J Nanobiotechnology

Biosynthesized nanoparticles of Tibetan medicine mercuric sulfide preparation to promote endocytosis and realize drug crossing through blood brain barrier. [Abstract]

2025 Jun 16;23(1):445. PMID: 40524151
J Nanobiotechnology

Biosafe cerium oxide nanozymes protect human pluripotent stem cells and cardiomyocytes from oxidative stress. [Abstract]

2024 Mar 26;22(1):132. PMID: 38532378
Sci Adv

Blocking the isoflavone chemoreceptor in Phytophthora sojae to prevent disease. [Abstract]

2025 Jan 10;11(2):eadt0925. PMID: 39772695
Small

Dynamically Reprograms Mitochondrial Respiration to Augment Cuproptosis in Cancer Therapy. [Abstract]

2026 Mar;22(18):e13435. PMID: 41653427
Small

Active Transportation of Liposome Enhances Tumor Accumulation, Penetration, and Therapeutic Efficacy. [Abstract]

2020 Nov;16(44):e2004172. PMID: 33030305
J Control Release

Dual-targeting fluorous peptide proteolysis-targeting chimeras for cancer therapy. [Abstract]

2025 Dec 30:114591. PMID: 41478376
J Control Release

Combating cisplatin-resistant lung cancer using a coiled-coil lipopeptides modified membrane fused drug delivery system. [Abstract]

2025 Jan 8:379:45-58. PMID: 39756686
J Hazard Mater

CYP450 activation and mitophagy induction mediate Ti3C2 MXene detoxification in RAW 264.7 cells. [Abstract]

2025 Dec 5:500:140498. PMID: 41252987
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Adv Healthc Mater

Self-Assembled Nanoparticles with Well-Defined Oligosaccharide Promote Osteogenesis by Regulating Golgi Stress Response. [Abstract]

2024 Dec 1:e2402976. PMID: 39618007
Cell Commun Signal

Promoting AMPK/SR-A1-mediated clearance of HMGB1 attenuates chemotherapy-induced peripheral neuropathy. [Abstract]

2023 May 4;21(1):99. PMID: 37143083
Int J Biol Macromol

Investigation of the internalization and transport mechanism of Codonopsis Radix polysaccharide both in mice and Caco-2 cells. [Abstract]

2022 Aug 31:215:23-35. PMID: 35718143
Phytomedicine

CBX5 loss drives Pl3Kδ inhibitor resistance in mantle cell lymphoma and propolis restores sensitivity by inducing CBX5-mediated ferroptosis. [Abstract]

2025 May 27:143:156911. PMID: 40466505
Phytomedicine

Bioactive components of Jiedu Sangen decoction against colorectal cancer: A novel and comprehensive research strategy for natural drug development. [Abstract]

2025 Apr 21:142:156795. PMID: 40279966
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
ACS Appl Mater Interfaces

Supramolecular Engineering of Molecular Inhibitors in an Adaptive Cytotoxic Nanoparticle for Synergistic Cancer Therapy. [Abstract]

2020 Jan 8;12(1):1707-1720. PMID: 31816241
Sci Total Environ

Cadmium exacerbates liver injury by remodeling ceramide metabolism: Multiomics and laboratory evidence. [Abstract]

2024 May 1:923:171405. PMID: 38432385
Br J Pharmacol

A glycine-serine-alanine-rich peptide ameliorates Alzheimer-type neurodegeneration. [Abstract]

2023 Jul;180(14):1878-1896. PMID: 36727262
Br J Pharmacol

An orally available hypoglycaemic peptide taken up by caveolae transcytosis displays improved hypoglycaemic effects and body weight control in db/db mice. [Abstract]

2020 Aug;177(15):3473-3488. PMID: 32293707
Emerg Microbes Infect

Resveratrol inhibits African swine fever virus replication via the Nrf2-mediated reduced glutathione and antioxidative activities. [Abstract]

2025 Dec;14(1):2469662. PMID: 39964001
Environ Pollut

Comparative effects of genistein and bisphenol A on non-alcoholic fatty liver disease in laying hens. [Abstract]

2021 Nov 1:288:117795. PMID: 34274649
Cell Rep

TRESK channel contributes to depolarization-induced shunting inhibition and modulates epileptic seizures. [Abstract]

2021 Jul 20;36(3):109404. PMID: 34289346
Lebensm Wiss Technol

2025 Sep 8;233:118474.
Int J Nanomedicine

The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route. [Abstract]

2019 Nov 27;14:9217-9234. PMID: 31819426
J Agric Food Chem

Genistein Ameliorates Rifampicin-Undermined Hepatic Cholesterol Efflux via the CH25H-LXRα-ABCA Pathway. [Abstract]

2025 Dec 29. PMID: 41459645
Bioeng Transl Med

Nanoalbumin-prodrug conjugates prepared via a thiolation-and-conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T-cell infiltration. [Abstract]

2022 Jul 30;8(1):e10377. PMID: 36684090
Colloids Surf B Biointerfaces

A dual-functional mitochondrial probe for melanoma visualization and PI3K/AKT/mTOR-EMT signaling axis-mediated antitumor therapy. [Abstract]

2025 Jun 3:254:114847. PMID: 40482387
Food Funct

Polyphenol-rich extract from Torreya grandis peel attenuates lipopolysaccharide-induced inflammation in RAW264.7 macrophages via inhibition of the TLR4/NF-κB pathway. [Abstract]

2025 Sep 26. PMID: 41002170
Front Pharmacol

Exploring the Therapeutic Mechanism of Desmodium styracifolium on Oxalate Crystal-Induced Kidney Injuries Using Comprehensive Approaches Based on Proteomics and Network Pharmacology. [Abstract]

2018 Jun 13:9:620. PMID: 29950996
mBio

ATP1A1 enhances porcine reproductive and respiratory syndrome virus type 2 attachment and internalization. [Abstract]

2026 Apr 8;17(4):e0389625. PMID: 41773865
ACS Appl Polym Mater

2026 Feb 25.
mBio

The Na+-K+-ATPase alpha subunit is an entry receptor for white spot syndrome virus. [Abstract]

2025 Mar 12;16(3):e0378724. PMID: 39964166
Biol Proced Online

Establishment of a mouse lung cancer organoid model and its applications for therapeutic screening. [Abstract]

2025 Jun 16;27(1):21. PMID: 40524168
Structure

Triangulating variation in the population to define mechanisms for precision management of genetic disease. [Abstract]

2022 Aug 4;30(8):1190-1207.e5. PMID: 35714602
Front Cell Dev Biol

Licarin-B Exhibits Activity Against the Toxoplasma gondii RH Strain by Damaging Mitochondria and Activating Autophagy. [Abstract]

2021 Jun 11:9:684393. PMID: 34179016
Front Cell Dev Biol

Structural and Functional Characterization of Fibronectin in Extracellular Vesicles From Hepatocytes. [Abstract]

2021 Mar 18:9:640667. PMID: 33816490
Mol Nutr Food Res

Impact of Physiologically Relevant Genistein Exposure at Different Time Windows on Puberty Onset and Neuroendocrine Function in Female Rats. [Abstract]

2022 Dec;66(24):e2200486. PMID: 36106654
J Mol Med (Berl)

Klotho recovery by genistein via promoter histone acetylation and DNA demethylation mitigates renal fibrosis in mice. [Abstract]

2019 Apr;97(4):541-552. PMID: 30806715
Drug Metab Dispos

Metabolic flux analysis of bile acid biosynthesis acidic pathway in HepG2 cells reveals CYP8B1 inhibition of azole antifungals. [Abstract]

2025 Nov;53(11):100168. PMID: 41124962
J Cell Physiol

Genistein-induced DNA damage is repaired by nonhomologous end joining and homologous recombination in TK6 cells. [Abstract]

2019 Mar;234(3):2683-2692. PMID: 30070703
Sci Rep

Genistein enhances anti-PD-1 efficacy in melanoma by suppressing regulatory T cell differentiation and activity. [Abstract]

2025 Oct 22;15(1):36973. PMID: 41125717
J Dermatolog Treat

Engineering extracellular vesicles with macrophage membrane fusion for ameliorating imiquimod-induced psoriatic skin inflammation. [Abstract]

2023 Dec;34(1):2220445. PMID: 38073229
J Biol Chem

SARS-CoV-2 hijacks macropinocytosis to facilitate its entry and promote viral spike-mediated cell-to-cell fusion. [Abstract]

2022 Nov;298(11):102511. PMID: 36259516
Cardiovasc Toxicol

Genistein Alleviates Oxidative Stress and Inflammation in the Hypothalamic Paraventricular Nucleus by Activating the Sirt1/Nrf2 Pathway in High Salt-Induced Hypertension. [Abstract]

2022 Nov;22(10-11):898-909. PMID: 35986807
PLoS Genet

Juvenile hormone promotes paracellular transport of yolk proteins via remodeling zonula adherens at tricellular junctions in the follicular epithelium. [Abstract]

2022 Jun 27;18(6):e1010292. PMID: 35759519
Aquacult Rep

February 2022, 100930.
Mol Med Rep

Identification of metabolites associated with capecitabine‑induced hand‑foot syndrome using untargeted metabolomics in patients with cancer. [Abstract]

2025 Jul;32(1):203. PMID: 40377002
Food Chem Toxicol

Prenatal genistein exposure in rats affects pubertal onset and serum reproductive hormone levels in male offsprings via the hypothalamic-pituitary-gonadal axis. [Abstract]

2025 Aug:202:115498. PMID: 40320066
Vet Res

A novel high-throughput screen identifies phenazine-1-carboxylic acid as an inhibitor of African swine fever virus replication in primary porcine alveolar macrophages. [Abstract]

2025 Feb 8;56(1):37. PMID: 39923101
Toxicol Appl Pharmacol

Glycosylation on breast cancer cell surface promotes the internalization and enhances therapeutic efficacy of cationic antimicrobial peptide L-K6. [Abstract]

2025 Oct:503:117481. PMID: 40684813
Food Nutr Res

Inhibition of castration-resistant prostate cancer growth by genistein through suppression of AKR1C3. [Abstract]

2023 Jan 31:67. PMID: 36794010
Biol Reprod

Associations between isoflavone exposure and reproductive damage in adult males: evidence from human and model system studies. [Abstract]

2022 Nov 14;107(5):1360-1373. PMID: 35948002
Vet Microbiol

Epidermal growth factor receptor (EGFR) promotes uptake of bovine parainfluenza virus type 3 into MDBK cells. [Abstract]

2022 Aug:271:109488. PMID: 35691094
Virus Res

Muscovy duck reovirus enters susceptible cells via a caveolae-mediated endocytosis-like pathway. [Abstract]

2020 Jan 15;276:197806. PMID: 31704247
Biochem Biophys Res Commun

Genistein alleviates Osteoporosis by inhibiting the differentiation and autophagy of osteoclasts via regulating the CYLD/p62/RANKL axis. [Abstract]

2026 Apr 23:810:153457. PMID: 41764819
Syst Biol Reprod Med

Genistein affects gonadotrophin-releasing hormone secretion in GT1-7 cells via modulating kisspeptin receptor and key regulators. [Abstract]

2022 Apr;68(2):138-150. PMID: 34986716
Biochem Biophys Res Commun

Genistein protects against acetaminophen-induced liver toxicity through augmentation of SIRT1 with induction of Nrf2 signalling. [Abstract]

2020 Jun 18;527(1):90-97. PMID: 32446397
Biochem Biophys Res Commun

Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]

2018 Sep 3;503(1):297-303. PMID: 29890135
Mol Cell Toxicol

17 August 2022.
Genet Mol Biol

Periostin regulates osteogenesis of mesenchymal stem cells from ovariectomized rats through actions on the ILK/Akt/GSK-3β Axis. [Abstract]

2021 Sep 29;44(3):e20200461. PMID: 34591063
SSRN

2025 Sep 30.
SSRN

2025 Sep 8.
University of Toronto

2025.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
SSRN

2025 Mar 24.
bioRxiv

2025 Jan 03.
bioRxiv

2024 August 18.
SSRN

2024 Apr 23.

용액&용해도

In Vitro:

DMSO : ≥ 100 mg/mL (370.04 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7004 mL

18.5021 mL

37.0041 mL

5 mM

0.7401 mL

3.7004 mL

7.4008 mL

10 mM

0.3700 mL

1.8502 mL

3.7004 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3.75 mg/mL (13.88 mM); Clear solution

This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 3 mg/mL (11.10 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 3 mg/mL (11.10 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (18.50 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

The IC₅₀ values for Genistein are determined by the MTT assay. Briefly, the MTT assay is a colorimetric assay that is based on the ability of living but not dead cells to reduce a tetrazolium-based compound to a blue formazan product. The formazan crystals are solubilized in DMSO, and the absorbance is measured at 540 nm. The absorbance at 540 nm is proportional to the number of viable cells. The lC₅₀ values obtained with the MTT assay are compared with the lC₅₀ values obtained by counting viable cells using trypan blue dye exclusion and by tritiated thymidine incorporation into DNA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]^[3]

Mice^[2]
Balb/c male mice are used. Genistein is administered as follows: On days 1-30, Genistein once daily, interaperitoneally injecting. Morphine plus Genistein is administered as follows: On days 1-30, Genistein once daily plus morphine, interaperitoneally injecting (17, 18). The same volume of saline is administered. Mice are randomly divided into 8 groups (n=6). 1) Normal saline group (1 mL DW/daily); 2) Morphine treated group; 3) Genistein 1 mg/kg treated group; 4) Genistein 2 mg/kg treated group 5) Genistein 4 mg/kg treated group; 6) Morphine plus Genistein 1 mg/kg treated group; 7) Morphine plus Genistein 2 mg/kg treated group; 8) Morphine plus Genistein 4 mg/kg treated group.
Rats^[3]
Male 8-week-old Wistar rats (150-180g) are used. After one week acclimation, all rats are randomly divided into 8 groups with 10 rats per group and treated for 35 weeks as follows: (1) STD group is fed with rodent standard chow diet (STD); (2) STD-BPA group is fed with STD and administered with BPA (50 μg/kg/day); (3) STD-(BPA+G) group is fed with STD and administered with BPA (50 μg/kg/day) plus Genistein (10 mg/kg/day); (4) STD-G group is fed with STD and administered with Genistein (10 mg/kg/day); (5) HFD group received high-fat diet (HFD); (6) HFD-BPA group is fed with HFD and administered with BPA (50 μg/kg/day); (7) STD-(BPA+G) group is fed with HFD and administered with BPA (50 μg/kg/day) plus Genistein (10 mg/kg/day); (8) HFD-G group is fed with HFD and administrated with Genistein (10 mg/kg/day). All the male genitors are treated for 35 weeks consecutively. The details of BPA (50 μg/kg/day) and Genistein (10 mg/kg/day) treatment methods have been described previously: BPA is dissolved in corn oil and diluted with three stock solutions (20, 40, 80, and 120 μg/mL).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Peterson G, et al. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 1996 Oct;7(10):1345-51. [Content Brief]

[2]. Ding S, et al. Environmentally Relevant Dose of Bisphenol A Does Not Affect Lipid Metabolism and Has No Synergetic or Antagonistic Effects on Genistein's Beneficial Roles on Lipid Metabolism. PLoS One. 2016 May 12;11(5):e0155352. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7004 mL	18.5021 mL	37.0041 mL	92.5104 mL
	5 mM	0.7401 mL	3.7004 mL	7.4008 mL	18.5021 mL
	10 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2510 mL
	15 mM	0.2467 mL	1.2335 mL	2.4669 mL	6.1674 mL
	20 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	25 mM	0.1480 mL	0.7401 mL	1.4802 mL	3.7004 mL
	30 mM	0.1233 mL	0.6167 mL	1.2335 mL	3.0837 mL
	40 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	50 mM	0.0740 mL	0.3700 mL	0.7401 mL	1.8502 mL
	60 mM	0.0617 mL	0.3084 mL	0.6167 mL	1.5418 mL
	80 mM	0.0463 mL	0.2313 mL	0.4626 mL	1.1564 mL
	100 mM	0.0370 mL	0.1850 mL	0.3700 mL	0.9251 mL

Keywords

Genistein

88 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Genistein

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Anti-COVID-19 Compound Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Flavonoids Library

Anti-Hepatitis C Virus Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Chemotherapy Drug Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Aging Natural Product Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Bacteria-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Genistein

All EGFR Isoforms

All Endogenous Metabolite Isoforms